评估PI-RADS v2 ≥3类对临床显著性前列腺癌的诊断价值
该回顾性队列纳入47例接受3.0T多参数MRI及经会阴模板穿刺活检的男性,由两名放射科医师独立按PI-RADS v2评分,第三名医师仲裁。病灶水平PI-RADS 5类阳性预测值及特异度均达100%;PI-RADS ≥3类诊断临床显著性前列腺癌的敏感度在Gleason评分≥7组为68.27%、肿瘤体积≥0.5 cc组为48.39%。
要点
- PI-RADS v2 5类病灶的阳性预测值和特异度均为100%。
- 病灶水平PI-RADS ≥3类诊断Gleason评分≥7癌的敏感度为68.27%。
- 病灶水平PI-RADS ≥3类诊断肿瘤体积≥0.5 cc癌的敏感度为48.39%。
核心结论
- PI-RADS v2 5类具有高阳性预测值和特异度;但合并PI-RADS ≥3类在检出临床显著性前列腺癌方面表现不一。
研究设计与样本
- IRB批准的回顾性队列研究,纳入47例接受3.0T多参数MRI和经会阴模板穿刺活检的男性;两名放射科医师独立评估T2、DWI、ADC图及DCE图像并按PI-RADS v2分类,第三名放射科医师仲裁;以基于前列腺分区的经会阴模板穿刺活检三维模型结果为参考标准。
诊断标准与关键数值
- PI-RADS v2评分≥3的病灶与经会阴模板穿刺活检三维模型结果按前列腺分区进行关联分析。
- 临床显著性前列腺癌分别按Gleason评分≥7(第1组)和肿瘤体积≥0.5 cc(第2组)两种标准独立分析准确性指标。
- 病灶水平:PI-RADS ≥3类诊断第1组癌的敏感度为68.27%、特异度为93.56%;诊断第2组癌的敏感度为48.39%、特异度为95.53%。
- 个体水平:PI-RADS ≥3类诊断第1组癌的敏感度为81.25%、特异度为32.26%;诊断第2组癌的敏感度为82.35%、特异度为53.85%。
- PI-RADS 5类在病灶水平和个体水平的阳性预测值及特异度均为100%。
临床应用与阅片要点
- 阅片时可按PI-RADS v2分类报告前列腺病灶,并注意5类病灶具有高阳性预测值和特异度。
- 需注意PI-RADS ≥3类合并分析时敏感度在Gleason评分≥7组与肿瘤体积≥0.5 cc组间存在差异。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: To assess the diagnostic accuracy of PI-RADS v2 categories ≥ 3 to detect clinically significant prostate cancer (csPCa) against histopathology of Transperineal Mapping Biopsy (TPMB).
MATERIALS AND METHODS: IRB-approved retrospective cohort study included 47 men who had 3.0 T multi-parametric MRI (mpMRI) and TPMB of prostate. Two radiologists independently evaluated T2, DWI, ADC map, and DCE images using PI-RADS v2 categories. A third radiologist served as tie-breaker. PI-RADS v2 score (PS) ≥ 3 lesions were correlated with 3D model of TPMB (3DTPMB) results based on prostate sectors. Two groups of csPCa status were separately analyzed for accuracy measures at lesion and person levels: Group 1 with GS (Gleason Score) ≥ 7 and group 2 with tumor volume ≥ 0.5 cc. Inter-rater reliability for PS and MR lexicon was calculated.
RESULTS: Forty-seven patients with 3DTPMB had at least one lesion with PS ≥ 3 on mpMRI. PS of 5 had high PPV and high specificity of 100% at the lesion and person levels. Sensitivity of a PS ≥ 3 was 68.27% for group 1 and was 48.39% for group 2. Specificity was 93.56% for group 1 and was 95.53% for group 2. At the person level, sensitivity of PS ≥ 3 was 81.25% for group 1 and was 82.35% for group 2. Specificity was 32.26% for group 1 and was 53.85% for group 2.
CONCLUSION: PI-RADS v2 category of 5 had high PPV and specificity; however, combined PS ≥ 3 had mixed performance in detection of csPCa.
引用
- Patel NU, Lind KE, Garg K, et al. Assessment of PI-RADS v2 categories ≥ 3 for diagnosis of clinically significant prostate cancer. Abdom Radiol (NY). 2019. PMID: 30171296. doi:10.1007/s00261-018-1751-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。